This is hard way of doing things --
A very recent publication by Gill D et al. available on bioRxiv claims to have developed an unprecedented transcription factor rejuvenation technology to rejuvenate human fibroblasts for as much as 30 years (as measured by a novel transcriptome clock) [206]. A technology called maturation phase transient reprogramming (MPTR) involves transfection of a polycistronic cassette with OCT4, SOX2, KLF4, c-MYC, and GFP genes under the control of a doxycycline promoter. Genes were expressed ectopically until maturation was reached, after which expression was turned off. MPTR has been shown to significantly rejuvenate all measured molecular signs of aging such as the epigenome, including H3K9me3 histone methylation levels and the DNA methylation aging clock without loss of cell identity.
https://www.mdpi.com.../11/11/1050/htm
They've achieved a reversal of "as much as 30 years" with cells in a dish using a genetic treatment via a retrovirus vector, whereas I've shown a reversal of 28 years with oral supplements.
As for my previous post about the mTor inhibitors --
Despite the limited clinical success of the first-generation drugs, rapamycin and its analogs (which are known as rapalogs)...
Both animal and clinical studies have shown that rapalogs are primarily cytostatic
https://www.ncbi.nlm...les/PMC3069769/
Cytostatic means it inhibits proliferation. And while rapalogs may inhibit proliferation of stem cells, they can promote cancer cell stemness --
Here, we describe a novel H-ras specific feedback, which leads to an inadvertent rapalog induced activation of tumorigenicity
https://pubmed.ncbi....h.gov/28562352/
So to use mTor inhibitors to achieve fusion (doubtful) or to increase telomerase (not generally desirable in this protocol, anyway) is not advised.
Edited by Turnbuckle, 08 April 2022 - 11:13 AM.